5462-86-2

Basic information

• Product Name: 6-Chloro-9-Ethyl-9H-Purine
• Synonyms: 6-chloro-9-ethylpurine;6-chloro-9-ethyl-purine
• CAS NO: 5462-86-2
• Molecular Formula: C₇H₇ClN₄
• Molecular Weight: 182.61
• Mol File: 5462-86-2.mol

Chemical Properties

• Boiling Point: 326.9°Cat760mmHg
• Flash Point: 151.5°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 0.000209mmHg at 25°C
• Refractive Index: 1.705
• CAS DataBase Reference: 6-Chloro-9-Ethyl-9H-Purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-9-Ethyl-9H-Purine(5462-86-2)
• EPA Substance Registry System: 6-Chloro-9-Ethyl-9H-Purine(5462-86-2)

Safety Data

• Hazardous Substances Data: 5462-86-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-9-Ethyl-9H-Purine is used as a key intermediate in the synthesis of nucleotide analogs for the development of antiviral and anticancer drugs. Its unique structure allows for the creation of compounds with specific therapeutic properties, making it a valuable component in drug discovery and design.
Used in Organic Synthesis:
6-Chloro-9-Ethyl-9H-Purine is used as a building block in organic synthesis, enabling the creation of a wide range of purine derivatives with diverse applications. Its chemical properties and reactivity make it a versatile compound for the synthesis of complex organic molecules.
Used in Medicinal Chemistry Research:
6-Chloro-9-Ethyl-9H-Purine is employed in medicinal chemistry research to explore its potential as a therapeutic agent and to understand its interactions with biological targets. Its unique structure and properties provide insights into the design of novel drugs and the optimization of existing ones.

InChI:InChI=1/C7H7ClN4/c1-2-12-4-11-5-6(8)9-3-10-7(5)12/h3-4H,2H2,1H3

Upstream product

• 14036-06-7 diethoxymethyl acetate 
• 98140-03-5 6-chloro-N⁴-ethylpyrimidine-4,5-diamine 
• 75-03-6 ethyl iodide 
• 87-42-3 6-chloropurine 
• 64-17-5 ethanol 
• 66224-66-6 adenine 
• 74-96-4 ethyl bromide 
• 87-42-3 6-chloro-7H-purine 
• 2715-68-6 9-ethyladenine 

Downstream Products

• 135394-09-1 Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine 
• 25870-60-4 6-(benzylamino)-9-ethylpurine 
• 15923-47-4 9-ethyl-6-(octylthio)-9H-purine 
• 5427-20-3 9-Ethyl-9H-purin-6(1H)-thion 

Relevant articles and documents

Deaminative chlorination of aminoheterocycles

Selective modification of heteroatom-containing aromatic structures is in high demand as it permits rapid evaluation of molecular complexity in advanced intermediates. Inspired by the selectivity of deaminases in nature, herein we present a simple methodology that enables the NH2 groups in aminoheterocycles to be conceived as masked modification handles. With the aid of a simple pyrylium reagent and a cheap chloride source, C(sp2)?NH2 can be converted into C(sp2)?Cl bonds. The method is characterized by its wide functional group tolerance and substrate scope, allowing the modification of >20 different classes of heteroaromatic motifs (five- and six-membered heterocycles), bearing numerous sensitive motifs. The facile conversion of NH2 into Cl in a late-stage fashion enables practitioners to apply Sandmeyer- and Vilsmeier-type transforms without the burden of explosive and unsafe diazonium salts, stoichiometric transition metals or highly oxidizing and unselective chlorinating agents. [Figure not available: see fulltext.]

Projected Dose Optimization of Amino- And Hydroxypyrrolidine Purine PI3KδImmunomodulators

The approvals of idelalisib and duvelisib have validated PI3Kδinhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors wit

Synthesis of novel selenotetrazole purine derivatives and their potential chemotherapeutic activities

The development of novel chemotherapeutic agents is indispensable to improve cancer treatment. One of the conventional approaches toward the synthesis of anticancer agents is the design of a compound whose structure is similar to purines found in DNA. In this study, a series of novel artificial purine nucleosides bearing selenotetrazole pharmacophore, 4a–4h, were synthesized. In order to get preliminary information about their cytotoxic activities, the interaction of compounds with DNA was investigated by UV titration and agarose gel electrophoresis and transcription inhibition studies were performed. The cytotoxic effects of the compounds against B16 melanoma, OV90 ovarian cancer, JM1 lymphoma cell lines, and PHA-induced peripheral blood lymphocytes were also investigated. In cell assay studies, the effects of the compounds on synthesis and mitosis stage of cell cycle were compared by flow cytometry. Although none of the compounds synthesized interacted with DNA and exhibited transcription inhibition, all of them significantly inhibited DNA synthesis phase and showed cytotoxic activity on cancer and proliferating cells. [Figure not available: see fulltext.]

Purine-ring-containing benzene sulfonamide chalcone derivative and preparation and application methods thereof

The invention discloses a purine-ring-containing benzene sulfonamide chalcone derivative and preparation and application methods thereof. The purine-ring-containing benzene sulfonamide chalcone derivative has a formula (I) shown as below, in which R1 is 4-oxymethyl, 4-tert-butyl, 4-methyl, 4-flouride, 4-bromide, 2-methyl, 2-fluoride, 2-chloride, 2-bromide and hydrogen atom and R2 is methyl, ethyland benzyl. The purine-ring-containing benzene sulfonamide chalcone derivative can inhibit tobacco mosaic virus, cucumber mosaic virus, potato Y virus and southern rice black-streaked dwarf virus.

Antiviral properties and interaction of novel chalcone derivatives containing a purine and benzenesulfonamide moiety

A new concise and facile method was explored to synthesize a series of novel chalcone derivatives containing a purine and benzenesulfonamide moiety and their antiviral properties were evaluated against TMV and CMV. Biological assays indicated that several

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

Provided are compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

Synthesis of some novel amino and thiotetrazole purine derivatives and investigation of their antimicrobial activity and DNA interactions

A series of amino and thiotetrazole purine derivatives introduced with different alkyl groups in position 9 was synthesized. The structures of the synthesized compounds were characterized using spectroscopic methods. All the synthesized compounds were screened for their antibacterial activities against Gram-positive and Gram-negative bacteria and for their antifungal activities against yeast strains. The effect of the compounds on pBR322 plasmid DNA was studied by gel electrophoretic mobility measurements. The results of antimicrobial activity show that attachment of tetrazole group to purine bases results in disappearance of antimicrobial activity The results of the plasmid DNA interaction and the restriction studies suggest that while aminotetrazole purine derivatives cause DNA damages, thiotetrazole purine derivatives are believed to form a range of interstrand GG adducts with duplex DNA that induce global changes in the DNA conformation.